

5. Bile acid binding resins - 4th line

MOA: Bind to bile acid and prevent absorption → ↓LDL

Cholestyramine

Cholestropol

Use: Hyperlipidemia

SE: GI bloating, greasy stools, changes in taste, ↑TGs, Gall stones.

DDI: Reduces absorption of lipophilic drugs: Thiazides, digoxin, warfarin**, iron, propranolol, statins

CI: intestinal inflammation, diverticulitis

4. Statins – 1st line

MOA: 1^o Inhibition of HMGCoA reductase → ↑LDL Receptor → ↓LDL

2^o ↑endothelial cell function (NO) → ↓platelet aggregation, anti-inflammatory/antioxidant → prevent formation of foam cells

Rosuvastatin, Atorvastatin - most potent

Simvastatin, Lovastatin – prodrugs, take in evening

Use: Hyperlipidemia, CAD, MI, ↓CV/stroke mortality

SE: Rhabdomyolysis (↑CK), myositis (isoprenoids), elevated liver enzymes, reduced insulin release (CCBs)

CI: Warfarin, pregnancy, amiodarone (simvastatin), CYP3A4 drugs (lovastatin, simvastatin, atorvastatin) CYP2C9 drugs (rosuvastatin)

3. Lomitapide

MOA: inhibit MTP → Prevent ApoB incorporation into VLDL → ↓LDL

Use: Familial hypercholesterolemia

PK: High albumin binding, extensive hepatic metabolism

SE: Abdominal discomfort, steatosis, elevated transaminases

7. PCSK9 inhibitors


MOA: Prevent breakdown of LDL receptors → LDL upregulation. → increased use

Evolocumab, Alirocumab – monoclonal antibodies

Use: Familial hypercholesterolemia

SE: Neural, delirium, neurocognitive effects

	Lipid effect
Statins	↓ LDL ↓ TG ↑ HDL
Fibrates	↓ LDL ↓ TG ↑ HDL
Bile acid resins	↓ LDL
Niacin	↓ LDL ↓ TG ↑↑ HDL
Ezetimibe	↓ LDL
PCSK9 inhibitors	↓ LDL



KEY
 LPL – lipoprotein lipase
 HSL – hormone sensitive lipase
 FFAs – Free fatty acids
 TGs – Triglycerides
 Enzymes
 Mechanism of action

6. Ezetimibe (prodrug) – 2nd line

MOA: inhibition of NPC1L1 → ↓cholesterol absorption → ↓LDL

Use: Hyperlipidemia – usually combined with statin*

SE: reversible liver damage (liver enzymes) – worse with statins, diarrhea

1. Nicotinic acid

MOA: Activate GP109A receptors → ↓HSL → ↓TGs → ↓VLDL, ↑HDL (decreased catabolism)

Use: Hyperlipidemia

SE: Vasodilation (give NSAIDs), hyperglycemia, hyperuricemia, hypotension, hepatotoxicity

CI: Pregnancy, peptic ulcer, liver damage

2. Fibrates – 3rd line

MOA: Activate PPARα receptors → Upregulate LPL → ↓TGs

Gemfibrozil

Fenofibrate

Use: Hypertriglyceridemia

SE: ↓platelet aggregation, ↓Fibrinogen levels, ↑t-PA production, gall stone formation

CI: Warfarin (PD), Statins (myositis), kidney/liver dysfunction